Related Experiment Video
Updated: Aug 4, 2026
09:07
An Orthotopic Model of Murine Bladder Cancer
Published on: February 6, 2011
Chemotherapy for metastatic bladder cancer
1Northern Centre for Cancer Treatment, Newcastle General Hospital, Newcastle upon Tyne, UK. trevor.roberts@nuth.nhs.uk
Clinical Oncology (Royal College of Radiologists (Great Britain))
|October 22, 2005
Summary
Systemic chemotherapy offers treatment options for advanced urothelial cancer, including survival benefits and roles before surgery. Research explores prognostic factors and future targeted therapies for better patient outcomes.
Area of Science:
- Oncology
- Urology
Background:
- Advanced and metastatic urothelial cancer presents significant treatment challenges.
- Systemic chemotherapy is a cornerstone in managing this disease, but optimal strategies are evolving.
Purpose of the Study:
- To review the current landscape of systemic chemotherapy for advanced urothelial cancer.
- To evaluate single agents, combination regimens, and prognostic factors influencing response and survival.
Main Methods:
- Review of existing literature on systemic chemotherapy in urothelial cancer.
- Analysis of randomized-controlled studies, prognostic factor data, and treatment strategies for specific patient groups.
Main Results:
- Various single agents and combination regimens show activity in advanced urothelial cancer.
- Prognostic factors impact response and long-term survival, with chemotherapy playing a role in neoadjuvant settings.
Conclusions:
- Systemic chemotherapy is integral to managing advanced urothelial cancer, offering survival benefits and neoadjuvant options.
- Future research should focus on molecular phenotyping and targeted therapies for improved treatment efficacy.
Related Concept Videos
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...